Development of Needle Free Alternatives for Treatment of Anaphylaxis Underway as Aquestive Therapeutics Launches Phase 1 Clinical Trial


DUBLIN–([1])– published a new article on the allergy drugs industry “Allergy Drugs” [2]

Nestle has agreed to buy Aimmune Therapeutics Inc in a $2.6 billion deal. Nestle has built a large health science business focused on dietary management and the deal will add Aimmunes’s Palforzia to its portfolio. Palforzia is the first FDA approved treatment to reduce the frequency and severity of allergic reactions to peanuts in children and teenagers. The drug is derived from peanut powder and works by exposing patients to escalating doses mixed with other foods. Palforzia is not intended to allow allergic patients to begin eating peanuts but rather to reduce the likelihood of serious reactions to accidental exposure. Nestle expects the deal to close in the fourth quarter.

Anxiety about using an epinephrine auto injector can be common among allergy patients and their families. This has led to interest in the development of needle free alternatives for treatment of anaphylaxis. Aquestive Therapeutics recently launched a phase 1 clinical trial of an epinephrine film that dissolves under the tongue. The trial will enroll up to 28 people and will compare the effectiveness of the film with epinephrine given by injection. If proven effective, a sublingual film could significantly reduce anxiety about administering epinephrine in cases of anaphylaxis.

To see the full article and a list of related reports on the market, visit Allergy Drugs[3]

About is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


  1. ^ (
  2. ^ “Allergy Drugs” (
  3. ^ Allergy Drugs (

Source URL: Read More
The public content above was dynamically discovered – by graded relevancy to this site’s keyword domain name. Such discovery was by systematic attempts to filter for “Creative Commons“ re-use licensing and/or by Press Release distributions. “Source URL” states the content’s owner and/or publisher. When possible, this site references the content above to generate its value-add, the dynamic sentimental analysis below, which allows us to research global sentiments across a multitude of topics related to this site’s specific keyword domain name. Additionally, when possible, this site references the content above to provide on-demand (multilingual) translations and/or to power its “Read Article to Me” feature, which reads the content aloud to visitors. Where applicable, this site also auto-generates a “References” section, which appends the content above by listing all mentioned links. Views expressed in the content above are solely those of the author(s). We do not endorse, offer to sell, promote, recommend, or, otherwise, make any statement about the content above. We reference the content above for your “reading” entertainment purposes only. Review “DMCA & Terms”, at the bottom of this site, for terms of your access and use as well as for applicable DMCA take-down request.

Acquire this Domain
You can acquire this site’s domain name! We have nurtured its online marketing value by systematically curating this site by the domain’s relevant keywords. Explore our content network – you can advertise on each or rent vs. buy the domain. | Skype: TLDtraders | +1 (475) BUY-NAME (289 – 6263). Thousands search by this site’s exact keyword domain name! Most are sent here because search engines often love the keyword. This domain can be your 24/7 lead generator! If you own it, you could capture a large amount of online traffic for your niche. Stop wasting money on ads. Instead, buy this domain to gain a long-term marketing asset. If you can’t afford to buy then you can rent the domain.

About Us
We are Internet Investors, Developers, and Incubators- operating a content network of several thousand sites while federating 20+ eCommerce and SaaS startups. With our proprietary “inverted incubation” model, we leverage a portfolio of $15M+ in valued domains to impact online trends, traffic, and transactions. We use robotic process automation, machine learning, and other proprietary approaches to power our content network. Discover our work!